An international team of researchers from Adelaide and the United States has engineered bacteria capable of detecting mutated DNA released from colorectal cancer cells, opening the door to faster disease detection.
Led by Dr Dan Worthley, Associate Professor Susan Woods and Dr Josephine Wright from SAHMRI and the University of Adelaide, in partnership with Professor Jeff Hasty at the University of California San Diego (UCSD), the study was published today in the prestigious journal, Science.
The team engineered bacteria called Acinetobacter baylyi (A. baylyi), which is known for its ability to sample and integrate DNA from its environment. Researchers leveraged this natural competence to detect the mutated KRAS gene, an important driver of colorectal cancer.
A/Prof Woods says they dubbed this technology ‘CATCH’, which stands for, Cellular Assay of Targeted CRISPR-discriminated Horizontal gene transfer.
“CATCH has the potential to detect bowel cancer early with the aim of preventing more people from dying of this and other cancers,” she said.
“This study demonstrates how bacteria can be designed to detect specific DNA sequences to diagnose disease in hard-to-reach places.”
In preclinical testing, the team found that the sensor bacteria were 100% accurate in differentiating between models with and without colorectal cancer.
“We were thrilled to see transfer of DNA from the tumour to the sensor bacteria,” A/Prof Woods said.
“This shows that our biosensing system can be used to catch colorectal cancer DNA within a complex ecosystem.”
Dr Dan Worthley says potential applications of the technology extend beyond cancer.
“In the future we will detect and prevent many diseases, including bowel cancer, with cells, not drugs,” he said.
“We hope that this invention, of life detecting life, will be useful for clinicians, scientists and engineers to help the community wherever and whenever DNA detection is important.”.
While further studies are needed before progressing to clinical trials, researchers are confident this latest discovery represents a significant advance in the field of living diagnostics while setting the stage for the timely and accurate delivery of targeted treatments.
-
Cancer survivorship and exercise oncology
Professor Sandra Hayes is the Director of Research at Cancer Council Queensland (CCQ), where she leads a comprehensive cancer research program encompassing cancer epidemiology, prevention, detection, treatment, and survivorship.
With a BAppSci (Hons) and a PhD in exercise oncology, Professor Hayes’s expertise lies in quantifying the impact of cancer diagnosis and treatment on physical and psychosocial wellbeing, quality of life, and survival. She also evaluates innovative supportive care strategies, particularly exercise, to improve post-cancer lives.
-
Applying artificial intelligence to medical imaging for cardiovascular disease detection
Parmida is a software engineer and biomedical scientist whose research focuses on translating novel medical imaging technologies into clinical practice to improve the diagnosis and management of cardiovascular disease.
Her current work applies advanced deep learning techniques to retinal polarization-sensitive optical coherence tomography (PS-OCT) imaging, aiming to generate clinically meaningful biomarkers and predictions of cardiovascular disease. Parmida’s collaboration partners include Fiona Stanley Hospital in Murdoch, Western Australia.
-
Novel forms of brain stimulation & psychedelic assisted psychotherapy
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
